Trial Outcomes & Findings for Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI) (NCT NCT01450800)

NCT ID: NCT01450800

Last Updated: 2017-02-13

Results Overview

The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

163 participants

Primary outcome timeframe

three weeks post-operative

Results posted on

2017-02-13

Participant Flow

Patients who received postoperative transurethral catheterization after surgery for pelvic organ prolapse, urinary incontinence, or both by the Division of Urogynecology at Duke University Medical Center from 8/2011 through 2/2013 were identified, recruited and enrolled after providing written informed consent at a routine pre-operative visit.

Randomization occurred within a few hours after surgery. Participants were excluded prior to randomization if they sustained intraoperative injury to the urinary tract requiring prolonged catheterization, or if they passed an immediate void trial on day of surgery (as these participants did not receive additional postoperative catheterization).

Participant milestones

Participant milestones
Measure
Nitrofurantoin
Randomized to nitrofurantoin 100mg daily for each day of catheterization for up to 7 days
Placebo
Randomized to placebo 1 tablet daily for each day of catheterization for up to 7 days
Overall Study
STARTED
82
81
Overall Study
COMPLETED
81
78
Overall Study
NOT COMPLETED
1
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Nitrofurantoin
Randomized to nitrofurantoin 100mg daily for each day of catheterization for up to 7 days
Placebo
Randomized to placebo 1 tablet daily for each day of catheterization for up to 7 days
Overall Study
Protocol Violation
1
3

Baseline Characteristics

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Nitrofurantoin
n=82 Participants
Participants randomized to receive antibiotics instructed to take nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
Placebo
n=81 Participants
Participants randomized to receive placebo instructed to take placebo 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
Total
n=163 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
58 Participants
n=5 Participants
55 Participants
n=7 Participants
113 Participants
n=5 Participants
Age, Categorical
>=65 years
24 Participants
n=5 Participants
26 Participants
n=7 Participants
50 Participants
n=5 Participants
Age, Continuous
57 years
STANDARD_DEVIATION 13 • n=5 Participants
57 years
STANDARD_DEVIATION 13 • n=7 Participants
57 years
STANDARD_DEVIATION 13 • n=5 Participants
Gender
Female
82 Participants
n=5 Participants
81 Participants
n=7 Participants
163 Participants
n=5 Participants
Gender
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
82 participants
n=5 Participants
81 participants
n=7 Participants
163 participants
n=5 Participants

PRIMARY outcome

Timeframe: three weeks post-operative

Population: Intent-to-treat analysis

The primary outcome was treatment for UTI within the first 3 weeks after surgery. Treatment for UTI was defined to include any treatment received for clinically suspected or culture-proven urinary tract infection within 3 weeks of surgery. Clinically suspected treatment was defined to include treatment given empirically upon development of urinary symptoms or prescribed based on urine test results. Culture-proven UTI was defined as a urine culture with greater than 100,000 colony-forming units of a single organism.

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=81 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
n=78 Participants
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Urinary Tract Infections
18 participants
10 participants

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to vaginal estrogen therapy

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
participants with no UTI
131 participants
Other Risk Factors for UTI
participants with UTI not on vaginal estrogen
24 participants
Other Risk Factors for UTI
participants with UTI on vaginal estrogen
4 participants

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to history of recurrent UTIs

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
participants with no UTI
131 participants
Other Risk Factors for UTI
participants with UTI with recurrent UTI
4 participants
Other Risk Factors for UTI
participants with UTI with no recurrent UTI
24 participants

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to preoperative UTI treatment

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
participants without UTI
131 participants
Other Risk Factors for UTI
participants with UTI with preoperative UTI
3 participants
Other Risk Factors for UTI
participants with UTI with no preoperative UTI
25 participants

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to Creatinine Clearance

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
Participants with UTI
115 mL/min
Standard Deviation 37
Other Risk Factors for UTI
Participants without UTI
101 mL/min
Standard Deviation 30

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to sling as part of surgery

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
participants with no UTI
131 participants
Other Risk Factors for UTI
participants with UTI with sling
16 participants
Other Risk Factors for UTI
participants with UTI with no sling
12 participants

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to total postoperative catheter days

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
Participants with UTI
2 days of catheterization
Interval 1.0 to 4.0
Other Risk Factors for UTI
participants without UTI
1 days of catheterization
Interval 1.0 to 3.0

SECONDARY outcome

Timeframe: 3 weeks following surgery

Population: Used entire study population to determine risk factors for UTI

We examined risk of UTI as related to postoperative catheter type

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=159 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Other Risk Factors for UTI
participants without UTI
131 participants
Other Risk Factors for UTI
participants with UTI with Foley
25 participants
Other Risk Factors for UTI
participants with UTI with self-catheterization
3 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 6 weeks after surgery

Population: Examined urine cultures with susceptibility testing results for all participants who had positive urine culture results

We examined for macrobid resistance on urine culture results within 3 weeks of surgery

Outcome measures

Outcome measures
Measure
Nitrofurantoin
n=9 Participants
Randomized to nitrofurantoin 100mg daily while using a catheter for up to 7 days
Placebo
Randomized to placebo 1 tab daily while using a catheter for up to 7 days
Antibiotic Resistance to Macrobid
1 urine culture resistant to nitrofurantoi

Adverse Events

Nitrofurantoin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Alexis Dieter

Duke University Medical Center

Phone: 919-401-1006

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place